GLP-1 Drugs Linked to Lower Risk of Depression and Anxiety in Large New Study
A large study tracking nearly 100,000 individuals found that GLP-1 drugs such as semaglutide, sold as Ozempic and Wegovy, are associated with a lower risk of depression and anxiety. The research, published in May 2026, adds to growing evidence that these medications may offer mental health benefits beyond weight loss and blood sugar control. Researchers say more study is needed before the drugs are prescribed specifically for mental health conditions.
A large study tracking nearly 100,000 individuals has found that GLP-1 drugs, including semaglutide, sold under the brand names Ozempic and Wegovy, are linked to a lower risk of depression and anxiety.
The research, published in May 2026, adds to a growing body of evidence suggesting these medications may offer mental health benefits beyond their primary uses for diabetes management and weight loss.
Researchers tracked participants over an extended period and found that those taking GLP-1 drugs had measurably lower rates of depression and anxiety diagnoses compared to control groups. The association held even after adjusting for factors such as weight loss, which itself can improve mood.
A separate meta-analysis published around the same time found that GLP-1 drugs do not increase the risk of depression or suicidality, a concern that had been raised in earlier safety reviews. That analysis also found modest improvements in quality of life and eating control among patients with diabetes or obesity.
Scientists are still working to understand the mechanism behind the potential mental health effects. Some researchers believe GLP-1 receptors in the brain may play a direct role in mood regulation. Others think the improvements may be partly explained by better metabolic health and reduced inflammation.
Experts caution that the findings do not yet support prescribing GLP-1 drugs specifically for depression or anxiety. The studies are observational, meaning they show an association but cannot prove the drugs directly cause the mental health improvements.
GLP-1 drugs have already shown promise in several other areas beyond their original indications. Earlier research linked them to improved breast cancer survival rates in women with obesity and type 2 diabetes, and a meta-analysis found they may help lower blood pressure.
The widespread use of GLP-1 drugs is also contributing to a decline in weight loss surgeries, as more patients and doctors opt for the medications instead.
